Concepedia

Publication | Open Access

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

DOIFull Paper Access

163

Citations

29

References

2019

Year

Aleix Prat, Tomás Pascual, Carmine De Angelis, Carolina Gutiérrez, Antonio Llombart‐Cussac, Tao Wang, Javier Cortés, Brent N. Rexer, Laia Paré, Andres Forero,
JNCI Journal of the National Cancer Institute

Abstract

Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-positive breast cancer.

References

YearCitations

Page 1